felodipine has been researched along with Obesity in 5 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim of this study was to compare the effect of valsartan and felodipine on blood pressure (BP), plasma leptin (L), insulin sensitivity and plasma norepinephrine (NE) in obese hypertensive patients." | 9.11 | Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2005) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Aim of this study was to compare the effect of valsartan and felodipine on blood pressure (BP), plasma leptin (L), insulin sensitivity and plasma norepinephrine (NE) in obese hypertensive patients." | 5.11 | Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2005) |
| "Calcium channel blockers, verapamil or felodipine, were given to genetically obese 6 and 11-month-old female SHHF/Mcc-facp (SHHF: Spontaneous Hypertension Heart Failure) rats for 8 weeks to investigate their effects on glucose and lipid metabolism and obesity." | 3.70 | Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats. ( Hoepf, T; McCune, SA; Park, SC; Radin, MJ, 1999) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Obesity is a significant risk factor for hypertension and the cardiovascular sequelae of hypertension." | 2.69 | The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. ( Adair, CT; Anderson, DC; Cameron, ME; Jones, DW; King, NS; Miller, ME; Willoughby, DL; Wofford, MR, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seravalle, G | 1 |
| Brambilla, G | 1 |
| Pizzalla, DP | 1 |
| Casati, A | 1 |
| Riva, M | 1 |
| Cuspidi, C | 1 |
| Bombelli, M | 1 |
| Mancia, G | 1 |
| Grassi, G | 1 |
| Fogari, R | 1 |
| Derosa, G | 1 |
| Zoppi, A | 1 |
| Rinaldi, A | 1 |
| Lazzari, P | 1 |
| Fogari, E | 1 |
| Mugellini, A | 1 |
| Preti, P | 1 |
| Scholze, J | 1 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Park, SC | 1 |
| Radin, MJ | 1 |
| Hoepf, T | 1 |
| McCune, SA | 1 |
| Jones, DW | 1 |
| Miller, ME | 1 |
| Wofford, MR | 1 |
| Anderson, DC | 1 |
| Cameron, ME | 1 |
| Willoughby, DL | 1 |
| Adair, CT | 1 |
| King, NS | 1 |
4 trials available for felodipine and Obesity
| Article | Year |
|---|---|
Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambula | 2016 |
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
Topics: Aged; Antihypertensive Agents; Felodipine; Female; Humans; Hypertension; Insulin Resistance; Leptin; | 2005 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1999 |
1 other study available for felodipine and Obesity
| Article | Year |
|---|---|
Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats.
Topics: Age Factors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Calcium C | 1999 |